A phase II study of first-line single agent of gefitinib in patients (pts) with stage IV non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Suzuki, R [1 ]
Hasegawa, Y [1 ]
Baba, K [1 ]
Saka, H [1 ]
Saito, H [1 ]
Taniguchi, H [1 ]
Yamamoto, M [1 ]
Matsumoto, S [1 ]
Kato, K [1 ]
Shimokata, K [1 ]
机构：
[1] Cent Japan Lung Study Grp, Nagoya, Aichi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：640S / 640S
页数：1
相关论文
共 50 条
  • [21] Phase II trial of docetaxel and gefitinib as first-line therapy for elderly patients with advanced non-small cell lung cancer (ANSCLC).
    Williams, CC
    Haura, EB
    Antonia, SJ
    Chiappori, A
    Bepler, G
    Simon, GR
    Moffitt, HL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 701S - 701S
  • [22] Chemotherapy beyond first-line in stage IV metastatic non-small cell lung cancer
    Younes, Riad Naim
    Pereira, Jost Rodrigues
    Fares, Abdo Latif
    Gross, Jefferson Luiz
    [J]. REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2011, 57 (06): : 686 - 691
  • [23] Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study
    Lu, Shun
    Zhou, Jian-Ying
    Niu, Xiao-Min
    Zhou, Jian-Ya
    Jian, Hong
    Yin, Hong-Yan
    Guan, Sha
    Wang, Lin-Fang
    Li, Ke
    He, James
    Su, Wei-Guo
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (02) : 839 - +
  • [24] FIRST-LINE ERLOTINIB IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING AN ACTIVATING EGFR MUTATION: A MULTICENTRE ACADEMIC PHASE II STUDY IN BELGIUM
    De Greve, Jacques
    Van Meerbeeck, Jan P.
    Vansteenkiste, Johan
    Teugels, Erik
    Geers, Caroline
    Meert, Anne-Pascale
    Vuylsteke, Peter
    Focan, Christian
    Canon, Jean-Luc
    Humblet, Yves
    Berchem, Guy J.
    Colinet, Benoit
    Galdermans, Daniella
    Bosquee, Lionel
    Dooms, Christophe
    Decoster, Lore
    Vermeij, Joanna
    Dewaele, Alex
    Schallier, Denis
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1270 - S1270
  • [25] Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
    Ji, Y.
    Wang, X.
    Lou, Z.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S979 - S979
  • [26] Retreatment of Gefitinib in the Patients with Non-Small Cell Lung Cancer (NSCLC) Previously Responded to Gefitinib, A Single Arm, Open Label, Phase II Study
    Oh, In Jae
    Ban, Hee-Jung
    Chi, Su-Young
    Cho, Hyun-Ju
    Tesden-Ish, Manaljav
    Kwon, Young-Soo
    Kim, Kyu-Sik
    Lim, Sung-Chul
    Kim, Young-Chul
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S401 - S401
  • [27] Phase II study of meloxicam with carboplatin plus docetaxel in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
    Ishida, T.
    Kanazawa, K.
    Oizumi, H.
    Yokouchi, H.
    Yamazaki, K.
    Akie, K.
    Sukoh, N.
    Harada, M.
    Munakata, M.
    Isobe, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC)
    Groen, H. J.
    Smit, E. F.
    Dingemans, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer
    Mir, Olivier
    Boudou-Rouquette, Pascaline
    Giroux, Julie
    Chapron, Jeanne
    Alexandre, Jerome
    Gibault, Laure
    Ropert, Stanislas
    Coriat, Romain
    Durand, Jean-Philippe
    Burgel, Pierre-Regis
    Dusser, Daniel
    Goldwasser, Francois
    [J]. LUNG CANCER, 2012, 77 (01) : 104 - 109
  • [30] A PHASE II STUDY OF SORAFENIB AND METFORMIN IN PATIENTS WITH STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC) WITH A KRAS MUTATION
    Mellema, Wouter W.
    Burgers, Sjaak
    Groen, Harry J. M.
    Dingemans, Anne-Marie
    Thunnissen, Erik
    Heideman, Danielle A. M.
    De Jong, Jeroen
    Timens, Wim
    Speel, Ernst-Jan M.
    Smit, Egbert F.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1205 - S1205
12345